Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 8593 - 8600 of 12086 results

FTC Again Urges Consideration of Competitive Impact on State Regulation of APRNs
February 17, 2016| Blog| Viewpoint

Sandoz Seeks High Court Take on Biosimilar Law
February 17, 2016| News

MintzEdge: A New Resource for Entrepreneurs
February 16, 2016| Blog| Viewpoint

Reducing Exposure to and Defeating Off-the-Clock OT Claims: A Ten-Step Plan
February 16, 2016| Blog| Viewpoint

A Preview of Business Immigration in 2016: Proposed Immigrant Visa Reforms (Part 3/6)
February 16, 2016| Blog| Viewpoint

Amidst the Raucous Debate in D.C., States Quietly Take Action on Rising Prescription Drug Prices
February 16, 2016| Blog| Viewpoint

CMS Notifies States of AMP Rule Requirements: 340B Providers Should Take Note
February 16, 2016| Blog| Viewpoint

Federal Circuit Declines to Disturb Established Precedent Regarding the Exhaustion of Patent Rights
February 16, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
